LGM Pharma launches analytical and stability testing as standalone service

The integrated CDMO rolls out services to the broader community of drug manufacturers and developers

The decision comes after the company's acquisition of Nexgen Pharma's formulation development and drug product contract manufacturing business last year, which LGM Pharma said "significantly expanded" its physical infrastructure and talent.

The additional 100,000 sq. ft of specialised facilities, equipment and 150 experienced staff with expertise in analytical and stability testing, along with expertise in all aspects of pharmaceutical finished product development and manufacturing, has placed LGM Pharma in a position to offer a full suite of these services as a standalone option.

The CDMO has a network of cGMP facilities in California, Colorado, and Texas, state-of-the-art chromatography and spectroscopy equipment, and more than 60 quality assurance, quality control and analytical staff members.